Although treatments for bladder cancer using antibody-based anti-PD-L1/PD1 and anti-CTLA-4 have shown to be clinically effective, they cannot currently satisfy the treatment needs of all patients, as most patients have exhibited a poor response to immunotherapy at various stages of bladder cancer. The gene discussed is PDCD1; the disease is urinary bladder carcinoma.